Cerebrolysin is a medicinal product containing a mixture of peptides derived from porcine brain proteins, rather than one isolated peptide. Neurological studies differ by patient group and endpoint; they do not establish better memory or focus in healthy people.
What does Cerebrolysin contain?
Product information on EVER Pharma Poland’s website identifies a porcine-brain-derived peptide mixture supplied as a solution for injection or infusion. It should not be described as one synthetic peptide or used as another name for a substance such as Semax. EVER Pharma Poland — Cerebrolysin Summary of Product Characteristics
This article discusses the documented product. It does not verify that every catalogue listing or vial bearing the name Cerebrolysin has matching composition or quality.
What does brain research show?
CASTA: an ischemic stroke trial
CASTA was a double-blind, placebo-controlled randomized trial enrolling 1,070 patients with ischemic stroke. Its main combined outcome was not significantly different between groups. Later subgroup findings should not replace the overall result with a claim of effectiveness for every patient. Heiss et al., 2012 — CASTA randomized stroke trial
CARS: arm function during rehabilitation
In CARS, 208 patients received standardized rehabilitation alongside study treatment. The Cerebrolysin group had better improvement on the Action Research Arm Test at day 90 than placebo. This concerned stroke rehabilitation, not memory enhancement in healthy adults. Muresanu et al., 2016 — CARS randomized rehabilitation trial
EVER Neuro Pharma funded the study, and several authors disclosed relationships with the company. These disclosures should be read alongside the design and results. CARS — Full report, funding and disclosures
2026 evidence after thrombectomy
A study of patients after clot-removal treatment compared Cerebrolysin recipients with historical controls matched on baseline characteristics. Treatment was associated with better functional independence at 12 months. This was observational, not randomized; the authors called for confirmation in multicenter randomized trials. Staszewski et al., 2026 — Matched cohort after thrombectomy
Does it improve memory in healthy people?
The studies above cannot answer that question. Recovering function after ischemic stroke differs from improving concentration or learning in healthy people. Laboratory mechanisms and findings for other products also cannot substitute for clinical evidence in this population.
What does the Thai registration record show?
The Thai FDA database displays CEREBROLYSIN, registration 1C 43/32, with protein hydrolysates, sterile solution, manufacturer EVER PHARMA JENA GMBH in Germany, and Chumitr 1967 Co., Ltd as license holder. Thai FDA — CEREBROLYSIN, 1C 43/32; database dated 30 June 2025
The database is dated 30 June 2025. It does not establish today’s registration status or availability. This record also cannot authenticate another source’s vial bearing the same name. The actual label, manufacturer, batch and documentation must match.
Important product-information limitations
EVER Pharma Poland’s information lists hypersensitivity, epilepsy and severe renal impairment as contraindications. The product is therefore not suitable for everyone. Foreign product information provides context for that product, but does not replace Thai-approved prescribing information or a clinician’s assessment. EVER Pharma Poland — Cerebrolysin Summary of Product Characteristics
Frequently asked questions
Is Cerebrolysin a single peptide?
No. Product information describes a porcine-brain-derived peptide mixture. The whole product and its manufacturing identity matter.
Is improved memory in healthy people established?
The examples discussed involve stroke patients. They do not establish improved memory or concentration in healthy people.
Is there a Thai Cerebrolysin record?
CEREBROLYSIN, registration 1C 43/32, appears in the Thai FDA database dated 30 June 2025. Current status and the actual product documentation still need checking.
Do studies verify every product bearing the same name?
No. A listing name alone does not verify composition, quality, authenticity or equivalence to the studied product.
Related reading
- NAD+: patient studies and the limits of anti-aging claims
- GHK-Cu: why formulation and product identity matter
General information enquiries
For questions about names, labels or documents, contact LINE: @musclestationth. Personal treatment decisions require a qualified healthcare professional.
Primary sources
- EVER Pharma Poland — Cerebrolysin Summary of Product Characteristics
- Thai FDA — CEREBROLYSIN, 1C 43/32; database dated 30 June 2025
- Heiss et al., 2012 — CASTA randomized stroke trial
- Muresanu et al., 2016 — CARS randomized rehabilitation trial
- CARS — Full report, funding and disclosures
- Staszewski et al., 2026 — Matched cohort after thrombectomy
Information checked: 11 September 2026. Educational information; no seller’s product or batch has been authenticated.